[et_pb_section fb_built=\u201d1\u2033 admin_label=\u201dsection\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d0px||0px||true|false\u201d global_colors_info=\u201d{}\u201d theme_builder_area=\u201dpost_content\u201d][et_pb_row admin_label=\u201drow\u201d _builder_version =\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d width=\u201d100%\u201d global_colors_info=\u201d{}\u201d theme_builder_area=\u201dpost_content\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding= \u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d theme_builder_area=\u201dpost_content\u201d][et_pb_image src=\u201dhttps:\/\/oncogen.oncoserv.ro\/wp-content\/uploads\/2023\/08\/diagnostic-molecular.jpg\u201d _builder_version=\u201d4.22.1\u2033 _module_preset=\u201ddefault\u201d theme_builder_area =\u201dpost_content\u201d title_text=\u201ddiagnostic molecular\u201d border_radii=\u201don|10px|10px|10px|10px\u201d hover_enabled=\u201d0\u2033 sticky_enabled=\u201d0\u2033][\/et_pb_image][et_pb_image src=\u201dhttps:\/\/oncogen.ro \/wp-content\/uploads\/2023\/08\/rosecan.png\u201d title_text=\u201drosecan\u201d _builder_version=\u201d4.22.1\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d theme_builder_area=\u201dpost_content\u201d][\/et_pb_image][et_pb_text admin_label=\u201dText\u201d _builder_version=\u201d4.22.1\u2033 text_font_size=\u201d17px\u201d text_line_height=\u201d28px\u201d background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d theme_builder_area=\u201dpost_content\u201d]<\/p>\n
Romania-Serbia Joint Initiative against Cancer in Cross-Border Region: Improved Diagnosis and Treatment of Malignant Tumors" - ROSECAN<\/strong><\/p>\n The OncoGen Center organized on October 25, 2019 the third Press Conference of the strategic project "Romania-Serbia joint initiative against cancer in the cross-border region: improving the diagnosis and treatment of malignant tumors - ROSECAN", financed by the Interreg-IPA program CBC Romania \u2013 Serbia.<\/p>\n The OncoGen Center has been equipped with all the equipment provided in the project for personalized diagnosis in cancer, by sequencing, currently the procurement procedure is underway for the development of a software dedicated to the diagnosis and treatment of oncological patients, which will be implemented in the cross-border region Romania - Serbia.<\/p>\n Next-generation gene sequencing (NGS) is a modern method used for precision diagnosis and therapy guidance in cancer, both for solid tumors and hematological malignancies. Gene sequencing provides us with information about mutations that occur in tumor cells during the process of tumor development and proliferation. Based on the panel of gene mutations appearing in a patient, he becomes a unique entity, with a personalized molecular diagnosis, thus benefiting from an individualized treatment. The information obtained is interpreted with the help of dedicated computer programs, such as Oncomine, IonReporter or VariantStudio. Through this methodology, new molecular targets existing at the level of tumors can be identified, thus being able to develop therapeutic strategies such as personalized vaccines or cellular immunotherapy.<\/p>\n Gene sequencing does not involve any risk for patients, as this method is performed from the DNA extracted from the paraffin-embedded tissue, after establishing the histopathological diagnosis of the tumor.<\/p>\n Through the gene sequencing program, OncoGen aligns itself with the current international anti-tumor diagnostic and therapeutic standards. Within the ROSECAN project, 3 new generation gene sequencing devices were purchased: Whole genome sequencing system with automatic sample preparation station (Ion Torrent Studio S5 + Ion Chef \u2013 ThermoFisher), targeted DNA sequencing system (Personal Genome Machine (PGM) \u2013 ThermoScientific) and MiSeq Sequencing System for validation (Illumina). These systems were used to analyze more than 80 samples this year, as follows:<\/p>\n Currently, at the level of the OncoGen Center, there is the possibility of performing about 100 more gene sequencing analyses.\u00a0\u00a0\u00a0<\/p>\n This successfully completed milestone brings us closer to achieving our goal of providing oncology patients with a personalized diagnosis and therapeutic guidance for the treatment of malignant tumors.<\/p>\n [\/et_pb_text][et_pb_code _builder_version=\u201d4.22.1\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d theme_builder_area=\u201dpost_content\u201d]\n